Asymptomatic hyperuricaemia: a silent activator of the innate immune system
Asymptomatic hyperuricaemia affects ~20% of the general population in the USA, with variable rates in other countries. Historically, asymptomatic hyperuricaemia was considered a benign laboratory finding with little clinical importance in the absence of gout or kidney stones. Yet, increasing evidenc...
Gespeichert in:
Veröffentlicht in: | Nature reviews. Rheumatology 2020-02, Vol.16 (2), p.75-86 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 86 |
---|---|
container_issue | 2 |
container_start_page | 75 |
container_title | Nature reviews. Rheumatology |
container_volume | 16 |
creator | Joosten, Leo A. B. Crişan, Tania O. Bjornstad, Petter Johnson, Richard J. |
description | Asymptomatic hyperuricaemia affects ~20% of the general population in the USA, with variable rates in other countries. Historically, asymptomatic hyperuricaemia was considered a benign laboratory finding with little clinical importance in the absence of gout or kidney stones. Yet, increasing evidence suggests that asymptomatic hyperuricaemia can predict the development of hypertension, obesity, diabetes mellitus and chronic kidney disease and might contribute to disease by stimulating inflammation. Although urate has been classically viewed as an antioxidant with beneficial effects, new data suggest that both crystalline and soluble urate activate various pro-inflammatory pathways. This Review summarizes what is known about the role of urate in the inflammatory response. Further research is needed to define the role of asymptomatic hyperuricaemia in these pro-inflammatory pathways.
Asymptomatic hyperuricaemia precedes and potentially contributes to the development of gout and other chronic diseases. This review summarizes what is known about the effects of uric acid on pro-inflammatory responses.
Key points
Hyperuricaemia is a common laboratory finding that precedes gout and is associated with gout, as well as with hypertension, acute and chronic kidney disease, obesity, metabolic syndrome, fatty liver and diabetes mellitus.
The causative role of elevated serum urate in these inflammatory conditions is controversial, but several urate-driven inflammatory mechanisms and other mechanisms have been described.
Urate crystals activate the NLRP3 inflammasome and contribute to IL-1β activation through autophagy dysfunction, diminished clearance of damaged organelles, altered redox status and/or AMP-activated protein kinase (AMPK) inhibition.
Urate crystals can promote inflammasome-independent mechanisms, such as serine protease-dependent activation of pro-inflammatory cytokines, formation of neutrophil extracellular traps and resolution of inflammation.
Soluble urate also has pro-oxidative effects in several cell types and induces inflammatory signalling through several mechanisms, such as MAPK pathway activation, AKT-mTOR activation or AMPK inhibition.
Soluble urate and hyperuricaemia exposure could alter the epigenetic programme of innate immune cells and contribute to common adult diseases by promoting persistent inflammatory hyperresponsiveness. |
doi_str_mv | 10.1038/s41584-019-0334-3 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2324909313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A612614352</galeid><sourcerecordid>A612614352</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-4004aed98e933e518e685c7b9bc0ebdb8f3aa3069a762a060cd5b6682b5733f33</originalsourceid><addsrcrecordid>eNp9kl1rFTEQhhex2Fr9Ad7IglC82Tr52Gzi3aHUDyx4o9chm53tSdlNjklWOP_eLKe1VrTkYgJ53pm8w1tVrwicE2DyXeKklbwBohpgjDfsSXVCulY1XAJ_enfvFBxXz1O6ARBcSPWsOmZEUioFPam-bNJ-3uUwm-xsvd3vMC7RWYOzM-9rUyc3oc-1sdn9NDnEOox13mLtvDe5lHlePNZpnzLOL6qj0UwJX97W0-r7h8tvF5-aq68fP19srhoroMsNB-AGByVRMYYtkShka7te9RawH3o5MmMYCGU6QQ0IsEPbCyFp33aMjYydVm8PfXcx_FgwZT27ZHGajMewJE0Z5QoUIyv65i_0JizRl99pyjuupOyIeJRiXBIgVME9dW0m1M6PIUdj19F6IwgVhLOWFur8H1Q5Q1mpDR7HstGHgrM_BFs0U96mMC3ZBZ8eguQA2hhSijjqXXSziXtNQK950Ic86JIHveZBr_5f3zpb-hmH34q7ABSAHoBUnvw1xnvr_-_6CxHNvAs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2348101290</pqid></control><display><type>article</type><title>Asymptomatic hyperuricaemia: a silent activator of the innate immune system</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Joosten, Leo A. B. ; Crişan, Tania O. ; Bjornstad, Petter ; Johnson, Richard J.</creator><creatorcontrib>Joosten, Leo A. B. ; Crişan, Tania O. ; Bjornstad, Petter ; Johnson, Richard J.</creatorcontrib><description>Asymptomatic hyperuricaemia affects ~20% of the general population in the USA, with variable rates in other countries. Historically, asymptomatic hyperuricaemia was considered a benign laboratory finding with little clinical importance in the absence of gout or kidney stones. Yet, increasing evidence suggests that asymptomatic hyperuricaemia can predict the development of hypertension, obesity, diabetes mellitus and chronic kidney disease and might contribute to disease by stimulating inflammation. Although urate has been classically viewed as an antioxidant with beneficial effects, new data suggest that both crystalline and soluble urate activate various pro-inflammatory pathways. This Review summarizes what is known about the role of urate in the inflammatory response. Further research is needed to define the role of asymptomatic hyperuricaemia in these pro-inflammatory pathways.
Asymptomatic hyperuricaemia precedes and potentially contributes to the development of gout and other chronic diseases. This review summarizes what is known about the effects of uric acid on pro-inflammatory responses.
Key points
Hyperuricaemia is a common laboratory finding that precedes gout and is associated with gout, as well as with hypertension, acute and chronic kidney disease, obesity, metabolic syndrome, fatty liver and diabetes mellitus.
The causative role of elevated serum urate in these inflammatory conditions is controversial, but several urate-driven inflammatory mechanisms and other mechanisms have been described.
Urate crystals activate the NLRP3 inflammasome and contribute to IL-1β activation through autophagy dysfunction, diminished clearance of damaged organelles, altered redox status and/or AMP-activated protein kinase (AMPK) inhibition.
Urate crystals can promote inflammasome-independent mechanisms, such as serine protease-dependent activation of pro-inflammatory cytokines, formation of neutrophil extracellular traps and resolution of inflammation.
Soluble urate also has pro-oxidative effects in several cell types and induces inflammatory signalling through several mechanisms, such as MAPK pathway activation, AKT-mTOR activation or AMPK inhibition.
Soluble urate and hyperuricaemia exposure could alter the epigenetic programme of innate immune cells and contribute to common adult diseases by promoting persistent inflammatory hyperresponsiveness.</description><identifier>ISSN: 1759-4790</identifier><identifier>EISSN: 1759-4804</identifier><identifier>DOI: 10.1038/s41584-019-0334-3</identifier><identifier>PMID: 31822862</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/420/2780 ; 692/420/2780/262 ; 692/699/1670/3/2765/1528 ; Antioxidants ; Asymptomatic ; Asymptomatic Diseases ; Biomarkers - metabolism ; Calculi ; Complications and side effects ; Cytokines - metabolism ; Diabetes mellitus ; Gout ; Health aspects ; Humans ; Hyperuricemia ; Hyperuricemia - immunology ; Hyperuricemia - metabolism ; Immune system ; Immunity, Innate ; Inflammation ; Innate immunity ; Kidney diseases ; Kidney stones ; Medicine ; Medicine & Public Health ; Nephrolithiasis ; Patient outcomes ; Review Article ; Rheumatism ; Rheumatology ; Uric acid ; Uric Acid - metabolism</subject><ispartof>Nature reviews. Rheumatology, 2020-02, Vol.16 (2), p.75-86</ispartof><rights>Springer Nature Limited 2019</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>2019© Springer Nature Limited 2019</rights><rights>Springer Nature Limited 2019.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-4004aed98e933e518e685c7b9bc0ebdb8f3aa3069a762a060cd5b6682b5733f33</citedby><cites>FETCH-LOGICAL-c607t-4004aed98e933e518e685c7b9bc0ebdb8f3aa3069a762a060cd5b6682b5733f33</cites><orcidid>0000-0003-3312-8193 ; 0000-0001-6166-9830</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41584-019-0334-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41584-019-0334-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31822862$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joosten, Leo A. B.</creatorcontrib><creatorcontrib>Crişan, Tania O.</creatorcontrib><creatorcontrib>Bjornstad, Petter</creatorcontrib><creatorcontrib>Johnson, Richard J.</creatorcontrib><title>Asymptomatic hyperuricaemia: a silent activator of the innate immune system</title><title>Nature reviews. Rheumatology</title><addtitle>Nat Rev Rheumatol</addtitle><addtitle>Nat Rev Rheumatol</addtitle><description>Asymptomatic hyperuricaemia affects ~20% of the general population in the USA, with variable rates in other countries. Historically, asymptomatic hyperuricaemia was considered a benign laboratory finding with little clinical importance in the absence of gout or kidney stones. Yet, increasing evidence suggests that asymptomatic hyperuricaemia can predict the development of hypertension, obesity, diabetes mellitus and chronic kidney disease and might contribute to disease by stimulating inflammation. Although urate has been classically viewed as an antioxidant with beneficial effects, new data suggest that both crystalline and soluble urate activate various pro-inflammatory pathways. This Review summarizes what is known about the role of urate in the inflammatory response. Further research is needed to define the role of asymptomatic hyperuricaemia in these pro-inflammatory pathways.
Asymptomatic hyperuricaemia precedes and potentially contributes to the development of gout and other chronic diseases. This review summarizes what is known about the effects of uric acid on pro-inflammatory responses.
Key points
Hyperuricaemia is a common laboratory finding that precedes gout and is associated with gout, as well as with hypertension, acute and chronic kidney disease, obesity, metabolic syndrome, fatty liver and diabetes mellitus.
The causative role of elevated serum urate in these inflammatory conditions is controversial, but several urate-driven inflammatory mechanisms and other mechanisms have been described.
Urate crystals activate the NLRP3 inflammasome and contribute to IL-1β activation through autophagy dysfunction, diminished clearance of damaged organelles, altered redox status and/or AMP-activated protein kinase (AMPK) inhibition.
Urate crystals can promote inflammasome-independent mechanisms, such as serine protease-dependent activation of pro-inflammatory cytokines, formation of neutrophil extracellular traps and resolution of inflammation.
Soluble urate also has pro-oxidative effects in several cell types and induces inflammatory signalling through several mechanisms, such as MAPK pathway activation, AKT-mTOR activation or AMPK inhibition.
Soluble urate and hyperuricaemia exposure could alter the epigenetic programme of innate immune cells and contribute to common adult diseases by promoting persistent inflammatory hyperresponsiveness.</description><subject>692/420/2780</subject><subject>692/420/2780/262</subject><subject>692/699/1670/3/2765/1528</subject><subject>Antioxidants</subject><subject>Asymptomatic</subject><subject>Asymptomatic Diseases</subject><subject>Biomarkers - metabolism</subject><subject>Calculi</subject><subject>Complications and side effects</subject><subject>Cytokines - metabolism</subject><subject>Diabetes mellitus</subject><subject>Gout</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Hyperuricemia</subject><subject>Hyperuricemia - immunology</subject><subject>Hyperuricemia - metabolism</subject><subject>Immune system</subject><subject>Immunity, Innate</subject><subject>Inflammation</subject><subject>Innate immunity</subject><subject>Kidney diseases</subject><subject>Kidney stones</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrolithiasis</subject><subject>Patient outcomes</subject><subject>Review Article</subject><subject>Rheumatism</subject><subject>Rheumatology</subject><subject>Uric acid</subject><subject>Uric Acid - metabolism</subject><issn>1759-4790</issn><issn>1759-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kl1rFTEQhhex2Fr9Ad7IglC82Tr52Gzi3aHUDyx4o9chm53tSdlNjklWOP_eLKe1VrTkYgJ53pm8w1tVrwicE2DyXeKklbwBohpgjDfsSXVCulY1XAJ_enfvFBxXz1O6ARBcSPWsOmZEUioFPam-bNJ-3uUwm-xsvd3vMC7RWYOzM-9rUyc3oc-1sdn9NDnEOox13mLtvDe5lHlePNZpnzLOL6qj0UwJX97W0-r7h8tvF5-aq68fP19srhoroMsNB-AGByVRMYYtkShka7te9RawH3o5MmMYCGU6QQ0IsEPbCyFp33aMjYydVm8PfXcx_FgwZT27ZHGajMewJE0Z5QoUIyv65i_0JizRl99pyjuupOyIeJRiXBIgVME9dW0m1M6PIUdj19F6IwgVhLOWFur8H1Q5Q1mpDR7HstGHgrM_BFs0U96mMC3ZBZ8eguQA2hhSijjqXXSziXtNQK950Ic86JIHveZBr_5f3zpb-hmH34q7ABSAHoBUnvw1xnvr_-_6CxHNvAs</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Joosten, Leo A. B.</creator><creator>Crişan, Tania O.</creator><creator>Bjornstad, Petter</creator><creator>Johnson, Richard J.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3312-8193</orcidid><orcidid>https://orcid.org/0000-0001-6166-9830</orcidid></search><sort><creationdate>20200201</creationdate><title>Asymptomatic hyperuricaemia: a silent activator of the innate immune system</title><author>Joosten, Leo A. B. ; Crişan, Tania O. ; Bjornstad, Petter ; Johnson, Richard J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-4004aed98e933e518e685c7b9bc0ebdb8f3aa3069a762a060cd5b6682b5733f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/420/2780</topic><topic>692/420/2780/262</topic><topic>692/699/1670/3/2765/1528</topic><topic>Antioxidants</topic><topic>Asymptomatic</topic><topic>Asymptomatic Diseases</topic><topic>Biomarkers - metabolism</topic><topic>Calculi</topic><topic>Complications and side effects</topic><topic>Cytokines - metabolism</topic><topic>Diabetes mellitus</topic><topic>Gout</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Hyperuricemia</topic><topic>Hyperuricemia - immunology</topic><topic>Hyperuricemia - metabolism</topic><topic>Immune system</topic><topic>Immunity, Innate</topic><topic>Inflammation</topic><topic>Innate immunity</topic><topic>Kidney diseases</topic><topic>Kidney stones</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrolithiasis</topic><topic>Patient outcomes</topic><topic>Review Article</topic><topic>Rheumatism</topic><topic>Rheumatology</topic><topic>Uric acid</topic><topic>Uric Acid - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joosten, Leo A. B.</creatorcontrib><creatorcontrib>Crişan, Tania O.</creatorcontrib><creatorcontrib>Bjornstad, Petter</creatorcontrib><creatorcontrib>Johnson, Richard J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joosten, Leo A. B.</au><au>Crişan, Tania O.</au><au>Bjornstad, Petter</au><au>Johnson, Richard J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Asymptomatic hyperuricaemia: a silent activator of the innate immune system</atitle><jtitle>Nature reviews. Rheumatology</jtitle><stitle>Nat Rev Rheumatol</stitle><addtitle>Nat Rev Rheumatol</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>16</volume><issue>2</issue><spage>75</spage><epage>86</epage><pages>75-86</pages><issn>1759-4790</issn><eissn>1759-4804</eissn><abstract>Asymptomatic hyperuricaemia affects ~20% of the general population in the USA, with variable rates in other countries. Historically, asymptomatic hyperuricaemia was considered a benign laboratory finding with little clinical importance in the absence of gout or kidney stones. Yet, increasing evidence suggests that asymptomatic hyperuricaemia can predict the development of hypertension, obesity, diabetes mellitus and chronic kidney disease and might contribute to disease by stimulating inflammation. Although urate has been classically viewed as an antioxidant with beneficial effects, new data suggest that both crystalline and soluble urate activate various pro-inflammatory pathways. This Review summarizes what is known about the role of urate in the inflammatory response. Further research is needed to define the role of asymptomatic hyperuricaemia in these pro-inflammatory pathways.
Asymptomatic hyperuricaemia precedes and potentially contributes to the development of gout and other chronic diseases. This review summarizes what is known about the effects of uric acid on pro-inflammatory responses.
Key points
Hyperuricaemia is a common laboratory finding that precedes gout and is associated with gout, as well as with hypertension, acute and chronic kidney disease, obesity, metabolic syndrome, fatty liver and diabetes mellitus.
The causative role of elevated serum urate in these inflammatory conditions is controversial, but several urate-driven inflammatory mechanisms and other mechanisms have been described.
Urate crystals activate the NLRP3 inflammasome and contribute to IL-1β activation through autophagy dysfunction, diminished clearance of damaged organelles, altered redox status and/or AMP-activated protein kinase (AMPK) inhibition.
Urate crystals can promote inflammasome-independent mechanisms, such as serine protease-dependent activation of pro-inflammatory cytokines, formation of neutrophil extracellular traps and resolution of inflammation.
Soluble urate also has pro-oxidative effects in several cell types and induces inflammatory signalling through several mechanisms, such as MAPK pathway activation, AKT-mTOR activation or AMPK inhibition.
Soluble urate and hyperuricaemia exposure could alter the epigenetic programme of innate immune cells and contribute to common adult diseases by promoting persistent inflammatory hyperresponsiveness.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31822862</pmid><doi>10.1038/s41584-019-0334-3</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3312-8193</orcidid><orcidid>https://orcid.org/0000-0001-6166-9830</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1759-4790 |
ispartof | Nature reviews. Rheumatology, 2020-02, Vol.16 (2), p.75-86 |
issn | 1759-4790 1759-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_2324909313 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | 692/420/2780 692/420/2780/262 692/699/1670/3/2765/1528 Antioxidants Asymptomatic Asymptomatic Diseases Biomarkers - metabolism Calculi Complications and side effects Cytokines - metabolism Diabetes mellitus Gout Health aspects Humans Hyperuricemia Hyperuricemia - immunology Hyperuricemia - metabolism Immune system Immunity, Innate Inflammation Innate immunity Kidney diseases Kidney stones Medicine Medicine & Public Health Nephrolithiasis Patient outcomes Review Article Rheumatism Rheumatology Uric acid Uric Acid - metabolism |
title | Asymptomatic hyperuricaemia: a silent activator of the innate immune system |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T17%3A52%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Asymptomatic%20hyperuricaemia:%20a%20silent%20activator%20of%20the%20innate%20immune%20system&rft.jtitle=Nature%20reviews.%20Rheumatology&rft.au=Joosten,%20Leo%20A.%20B.&rft.date=2020-02-01&rft.volume=16&rft.issue=2&rft.spage=75&rft.epage=86&rft.pages=75-86&rft.issn=1759-4790&rft.eissn=1759-4804&rft_id=info:doi/10.1038/s41584-019-0334-3&rft_dat=%3Cgale_proqu%3EA612614352%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2348101290&rft_id=info:pmid/31822862&rft_galeid=A612614352&rfr_iscdi=true |